InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.720 0.005 (0.69%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$303 DEP milestone triggers partner option fee 3 Jul 2026 9:29AM $0.710 $0.720 risen by 1.41%
$303 Positive DEP HER2-Lu preclinical data support Phase 1 entry 2 Jul 2026 9:22AM $0.710 $0.720 risen by 1.41%
$303 DEP radiopharmaceutical data supports patent application 2 Jul 2026 9:20AM $0.710 $0.720 risen by 1.41%
$303 Becoming a substantial holder 23 Jun 2026 6:06PM $0.695 $0.720 risen by 3.60%
$303 Becoming a substantial holder 17 Jun 2026 8:28AM $0.690 $0.720 risen by 4.35%
$303 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 10:15AM $0.705 $0.720 risen by 2.13%
$303 FDA confirms path to DEP HER2 first-in-human study 21 Apr 2026 9:40AM $0.680 $0.720 risen by 5.88%
$303 Becoming a substantial holder 15 Apr 2026 8:24AM $0.535 $0.720 risen by 34.58%
$303 Application for quotation of securities - SPL 7 Apr 2026 8:32AM $0.500 $0.720 risen by 44%
$303 Ceasing to be a substantial holder 12 Mar 2026 1:29PM $0.380 $0.720 risen by 89.47%
$303 Becoming a substantial holder 3 Mar 2026 8:04PM $0.400 $0.720 risen by 80%
$303 Half Yearly Report and Accounts 18 Feb 2026 8:37AM $0.480 $0.720 risen by 50%
$303 Ceasing to be a substantial holder 18 Feb 2026 8:10AM $0.480 $0.720 risen by 50%
$303 Ceasing to be a substantial holder 10 Feb 2026 3:42PM $0.410 $0.720 risen by 75.61%
$303 Change in substantial holding 10 Feb 2026 8:17AM $0.400 $0.720 risen by 80%
$303 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jan 2026 10:01AM $0.350 $0.720 risen by 105.71%
$303 Application for quotation of securities - SPL 7 Jan 2026 1:03PM $0.365 $0.720 risen by 97.26%
$303 Notification of cessation of securities - SPL 7 Jan 2026 12:58PM $0.360 $0.720 risen by 100%
$303 Change of Director's Interest Notice - C Maley 17 Dec 2025 2:14PM $0.345 $0.720 risen by 108.70%
$303 Notification regarding unquoted securities - SPL 17 Dec 2025 2:06PM $0.345 $0.720 risen by 108.70%
$303 Results of 2025 Annual General Meeting 14 Nov 2025 4:18PM $0.420 $0.720 risen by 71.43%
$303 AGM Chair address and CEO presentation 14 Nov 2025 1:05PM $0.410 $0.720 risen by 75.61%
$303 Quarterly Activities/Appendix 4C Cash Flow Report 28 Oct 2025 8:55AM $0.340 $0.720 risen by 111.76%
$303 Upfront payment of USD $5.5 million received from Genentech 22 Oct 2025 10:25AM $0.290 $0.720 risen by 148.28%
$303 Australian Microcap Investment Conference presentation 21 Oct 2025 3:30PM $0.300 $0.720 risen by 140%

1 - 25 of 856 results

Page 1 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.